EP4709380A1 - Schéma posologique de crinecerfont pour le traitement de l'hyperplasie surrénalienne congénitale chez un sujet pédiatrique - Google Patents

Schéma posologique de crinecerfont pour le traitement de l'hyperplasie surrénalienne congénitale chez un sujet pédiatrique

Info

Publication number
EP4709380A1
EP4709380A1 EP24729617.1A EP24729617A EP4709380A1 EP 4709380 A1 EP4709380 A1 EP 4709380A1 EP 24729617 A EP24729617 A EP 24729617A EP 4709380 A1 EP4709380 A1 EP 4709380A1
Authority
EP
European Patent Office
Prior art keywords
compound
dose
subject
glucocorticoid
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24729617.1A
Other languages
German (de)
English (en)
Inventor
Jean L. CHAN
Robert H. FARBER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of EP4709380A1 publication Critical patent/EP4709380A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne des méthodes d'administration de 4-(2-chloro-4-méthoxy-5-méthylphényl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-méthylphényl)éthyl]-5-méthyl-N-prop-2-ynyl-1,3-thiazol-2-amine, ou d'un sel pharmaceutiquement acceptable de celui-ci, chez un sujet pédiatrique atteint d'une hyperplasie surrénalienne congénitale.
EP24729617.1A 2023-05-08 2024-05-07 Schéma posologique de crinecerfont pour le traitement de l'hyperplasie surrénalienne congénitale chez un sujet pédiatrique Pending EP4709380A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363464697P 2023-05-08 2023-05-08
PCT/US2024/028110 WO2024233525A1 (fr) 2023-05-08 2024-05-07 Schéma posologique de crinecerfont pour le traitement de l'hyperplasie surrénalienne congénitale chez un sujet pédiatrique

Publications (1)

Publication Number Publication Date
EP4709380A1 true EP4709380A1 (fr) 2026-03-18

Family

ID=91302345

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24729617.1A Pending EP4709380A1 (fr) 2023-05-08 2024-05-07 Schéma posologique de crinecerfont pour le traitement de l'hyperplasie surrénalienne congénitale chez un sujet pédiatrique

Country Status (6)

Country Link
EP (1) EP4709380A1 (fr)
KR (1) KR20260005992A (fr)
AU (1) AU2024268015A1 (fr)
MX (1) MX2025013173A (fr)
TW (1) TW202444356A (fr)
WO (1) WO2024233525A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240605A1 (fr) * 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Traitement combiné

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
MA54395A (fr) 2018-12-07 2022-03-16 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
CR20220624A (es) * 2020-06-10 2023-07-06 Sanofi Sa Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita

Also Published As

Publication number Publication date
KR20260005992A (ko) 2026-01-12
WO2024233525A1 (fr) 2024-11-14
MX2025013173A (es) 2025-12-01
AU2024268015A1 (en) 2025-10-30
TW202444356A (zh) 2024-11-16

Similar Documents

Publication Publication Date Title
EP3984523B1 (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
Gruber et al. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial
US20230255942A1 (en) Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia
US20240398809A1 (en) Treatment of alopecia areata
US20240024330A1 (en) Crf receptor antagonists and methods of use
WO2024233525A1 (fr) Schéma posologique de crinecerfont pour le traitement de l'hyperplasie surrénalienne congénitale chez un sujet pédiatrique
Le Panse et al. Short-term glucocorticoid intake improves exercise endurance in healthy recreationally trained women
JP2026516082A (ja) 小児対象における先天性副腎過形成を処置するためのクリネセルフォントの投薬計画
WO2024206769A1 (fr) Régime posologique de crinecerfont pour le traitement de l'hyperplasie congénitale des surrénales
Horlen et al. Antihistamines (H1 receptor antagonists)
US12611383B1 (en) Pharmaceutical compositions for treating MCT8 deficiency
JP2022000473A (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
RU2824490C2 (ru) Антагонист рецептора crf1, его фармацевтические составы и твердые формы для лечения врожденной гиперплазии надпочечников
US20260083755A1 (en) Testosterone containing pharmaceutical composition
US20250381178A1 (en) Treatments for amyotrophic lateral sclerosis using dazucorilant
TWI916760B (zh) 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
HK40073040B (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
WO2025240605A1 (fr) Traitement combiné
KR20250144469A (ko) 헌팅턴병 및 이의 증상을 치료하기 위한 방법 및 조성물
EP4444286A1 (fr) Alz-801 destiné à être utilisé dans le traitement de la maladie d'alzheimer
WO2022238375A1 (fr) Méthodes de traitement de l'hypertension pulmonaire
HK1257770B (en) Treatment of alopecia areata

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR